Cyramza (ramucirumab)

The anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) monoclonal antibody ramucirumab was the first antiangiogenic agent approved for HER2-negative metastatic gastric adenocarcinomas and remains a standard second-line treatment either alone or in combination with paclitaxel. Other VEGFR-targeting agents, such as the tyrosine kinase inhibitors (TKI) regorafenib and apatinib, have failed to demonstrate any survival benefit in the first-line settings, while providing modest improvements in pretreated patients, even when combined with Immune Checkpoint Inhibitors (ICI)...Although several biomarker candidates have been explored, reliable predictors are still awaited. This review summarizes current evidence and explores the future of antiangiogenic agents in gastric cancers.

P2, N=30, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University

Moreover, treatment of HepG2 cells with S-MLPs led to a 12.99-fold increase in the activity of apoptotic proteins and decreased production of angiogenic proteins from 331.57 to 83.34 pg mL-1. The R2 relaxation value of 57.262 mM-1 s-1 obtained for the MLPs, indicating their high potential for clinical cancer management.

P2/3, N=212, Not yet recruiting, Gruppo Oncologico Del Nord Ovest

Across both databases, chemotherapy was the most common 1L regimen (approximately 50%), followed by nivolumab-containing regimens (34.7% in Medicare; 44.2% in MarketScan) and pembrolizumab-containing regimens (9.9% and 5.3%, respectively)...Nivolumab-containing regimens were the most common 2L treatment (36.3% in Medicare; 41.3% in MarketScan), whereas ramucirumab-containing regimens were most common in 3L (36.7% and 34.0%, respectively)...Analyses of recent data from the Medicare and MarketScan databases showed that most treated patients with HER2-negative advanced G/GEJC received standard chemotherapy in the 1L setting. Treatment of advanced G/GEJC remains associated with poor rwOS and high economic burden, suggesting significant remaining unmet need.

P2/3, N=172, Not yet recruiting, Gruppo Oncologico Del Nord Ovest

We report a case of metastatic CRC that achieved CR following second-line treatment with FOLFIRI plus ramucirumab after disease progression on first-line FOLFOX plus panitumumab therapy...In the present case, a watch-and-wait strategy was selected to prioritize organ preservation. Given the lack of consensus, further investigation is required to define the optimal strategy for patients achieving CR.

In conclusion, by causing cell cycle arrest and inducing apoptosis via mitochondrial malfunction and caspase pathway activation, ramucirumab demonstrates anti-cancer action against Caco-2 cells. These findings provide new perspectives on ramucirumab's wider anti-tumor potential beyond angiogenesis inhibition.

P1/2, N=45, Not yet recruiting, Gilead Sciences Inc.

P2, N=39, Recruiting, University of Chicago | Not yet recruiting --> Recruiting

P1/2, N=26, Not yet recruiting, Gilead Sciences Inc.

P2, N=59, Recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Apr 2026 --> Sep 2026 | Trial primary completion date: Apr 2026 --> Sep 2026